2023 was a standout year for MedRes, marked by achievements like opening a new USA office, expanding services, forming software partnerships, and driving CSR initiatives. Mr. Attila Meretei, CEO of MedRes, provided an overview of the company’s growth and future outlook.
What are the key drivers of growth for MedRes?
I think we are world class, yet affordable, with a complete offering. We have built a comprehensive list of capabilities. We can design and make components or finished devices, and we can support the regulatory process to get these new devices approved and commercialized for our clients. We work in almost every major clinical vertical. We have mechanical, electrical and software engineering capabilities to support every aspect of a new device R&D project. We have a footprint in the US and in the EU, we are close to the traditional med device hubs and yet offer a low-cost location for both R&D and manufacturing assignments. All that through a compact team, with rapid decision making.
How does MedRes measure its success and progress in the technology sector?
We consider financial performance, like everyone else does. We also pay attention to the impact the devices we work on will have in the clinic, benefiting providers and patients alike.
Can you highlight a project significantly contributing to MedRes’s growth?
MedRes was built on the successful launch of eight or nine major medical device platforms over the past 20 years. We have the next crop coming up in R&D, some of it rather late stage, migrating into manufacturing within months. It is important to us that we stand on many legs.
How does MedRes plan to sustain its growth and success in the long term?
Investing in people. Our own team of course, but also those we interact with at our clients. Their success is important to us. Also, investing in clinical knowledge. We nurture meaningful and long-term clinical relationships, so we can learn constantly, and get direct, rapid-fire advice from the end users on the devices we develop. We want our efforts to be based in clinical science and clinical evidence, therefore we are employing physicians and biologists alongside our engineers. Having clinical knowledge reside with our clients is not sufficient for good product development; we aim to possess that understanding as well. Finally, we also invest in our communities through outreach programs.
What emerging markets or sectors is MedRes targeting for future growth?
We are working in many fields of medicine, but we remain particularly excited about interventional cardiology and electrophysiology, women’s health, and the new field of interventional endoscopy. We aim to rapidly absorb knowledge in these evolving clinical specialties to be able to make meaningful impact on the engineering front.
Can you discuss any upcoming innovations or projects that MedRes is excited about?
Only our clients can discuss particular projects. Maybe the one exception is our budding partnership with Semmelweis University in creating a state-of-the-art catheter design and prototyping center.
How does MedRes envision its role in shaping the future of technology?
We hope to contribute by supporting clinical and technical innovators today and in the future in realizing their vision for new medical advances.